ArticleTransboundary and emerging diseases2022
Developing a gateway program for importing non-animal origin ingredients from regions with African swine fever virus.
Article in Transboundary and emerging diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Developing a gateway program for importing non-animal origin ingredients from regions with African swine fever virus.Transboundary and emerging diseases · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The US Department of Agriculture (USDA) categorizes the risk of African swine fever virus (ASFV) entry into the United States through non-animal origin feed ingredients as 'negligible to moderate, with high uncertainty'. Both Canada and Australia have implemented policies that are suggested to reduce the risk of ASFV entry through feed ingredients, but the United States has not because of scientific limitations that have been addressed by recent publications. As regulators and industry consider a potential pathway forward, the objective of this manuscript is to describe a process to determine if a voluntary or regulatory import policy is warranted by the United States. Initially, the volume and types of non-animal origin feed ingredients imported from countries with ASFV were quantified and assigned a level of risk (high risk: unprocessed grains and oilseeds, moderate risk: soybean co-products (meals, oil, and oilcake), and low risk: amino acids, vitamins, and other synthetically produced products from countries that have ASFV). In 2020, moderate- and high-risk ingredients from ASFV-positive countries represented 3.1% of all ingredients imported into the United States. Policies from Canada and Australia were evaluated for practicality of implementation by US government officials. Industry representatives from both countries consistently stated their policies would not be feasible in the United States due to the differences in cost and complexity of the swine and feed industries. Overall, unprocessed, or high-risk, ingredients from ASFV-positive countries represent a low percentage of imported ingredients into the United States; however, cautionary procedures may still be warranted given industry demand.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.